Clinical Trial

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid leukemia (AML) who are fit for intensive chemotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-13; most recent amendment 2026-02-26.
Status change: Not Yet Recruiting → Recruiting 2025-09-30
Trial Details
NCT Number NCT07132684
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions AML, Adult
Enrollment 240 participants
Start Date 2025-08-31
Primary Completion 2027-08-30 (estimated)
Study Completion 2028-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-02